Interactive Features

Quiz

Adjuvant Pembrolizumab Plus Chemotherapy for Patients With Newly Diagnosed, High-Risk Endometrial Cancer

11/12/2024

Based on results from the phase 3 ENGOT-en11/GOG-3053/KEYNOTE-B21 study, what was the estimated 2-year disease-free survival (DFS) rate for patients with newly diagnosed, high-risk endometrial cancer treated with pembrolizumab plus...

Based on results from the phase...

11/12/2024

Oncology

Quiz

Using the PREMM5 Model to Detect Mutations Associated With Lynch Syndrome

11/06/2024

Is the PREdiction Model for gene Mutations model able to accurately identify patients with endometrial cancer at risk of carrying mutations associated with Lynch Syndrome.

Is the PREdiction Model for gene...

11/06/2024

Oncology

Quiz

Response to Datopotamab Deruxtecan Among Patients With Endometrial Cancer

09/30/2024

In the TROPION-PanTumor03 study, what was the confirmed objective response rate among patients with endometrial cancer treated with datopotamab deruxtecan?

In the TROPION-PanTumor03 study,...

09/30/2024

Oncology

Quiz

Correlation Between Lymph Node Dissection at Hysterectomy and Survival in Patients With Endometrial Cancer

09/30/2024

According to results from a univariable and multivariable analysis, does lymph node dissection at the time of hysterectomy improve overall survival among patients with stage 3 endometrial cancer?

According to results from a...

09/30/2024

Oncology

Quiz

Well-Being and Quality of Life in Endometrial Cancer

08/28/2024

Do you know which factors can have the greatest impact on psychological well-being and overall quality of life among patients who have undergone surgery for endometrial cancer? Find out with our quiz.

Do you know which factors can...

08/28/2024

Oncology

Quiz

Sacituzumab Govitecan for Patients With Heavily Pretreated Advanced or Metastatic Endometrial Cancer

08/28/2024

Do you know whether sacituzumab govitecan showed promising efficacy among patients with heavily pretreated advanced or metastatic endometrial cancer? Test your knowledge with our quiz.

Do you know whether sacituzumab...

08/28/2024

Oncology

Quiz

Maintenance Selinexor for Patients With Advanced or First-Line Recurrent TP53 Wild-Type Endometrial Cancer

08/08/2024

Do you know whether maintenance selinexor demonstrated promising efficacy and safety among patients with advanced or first-line recurrent TP53 wild-type endometrial cancer?

Do you know whether maintenance...

08/08/2024

Oncology

Quiz

08/08/2024

Based on results from the phase 3 RUBY trial, the FDA expanded the approval of dostarlimab plus chemotherapy to include all patients with primary advanced or recurrent endometrial cancer. Do you know what the recommended dose of dostarlimab...

Based on results from the phase...

08/08/2024

Oncology

Quiz

Post-Progression Median PFS With Monotherapy for Endometrial Cancer

04/10/2024

What was the median progression-free survival for endometrial cancer treated with monotherapy after disease progression following initial treatment?

What was the median...

04/10/2024

Oncology

Quiz

Quiz: Does Post-Operative Chemotherapy and Radiation Improve OS in Endometrial Cancer?

08/10/2021

True or false: For high-risk patients with stage I endometrial cancer, post-operative systemic chemotherapy and radiotherapy was shown to improve overall survival.

True or false: For high-risk...

08/10/2021

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology